Results 181 to 190 of about 302,501 (282)

Pharmacy-level barriers to opioid overdose prevention: availability and accessibility of naloxone and buprenorphine-naloxone in high-risk Texas counties. [PDF]

Harm Reduct J
Darouiche KG, Malik MM, Mohr MT, Hagenimana MA, Digbeu BDE, Cunningham KA, Farr NM, Dostal CR.   +7 more
europepmc   +1 more source

High temporal resolution monitoring of illicit drug consumption across England via wastewater analysis

Addiction, Volume 121, Issue 8, Page 2043-2059, August 2026.
Abstract Aim To monitor community‐level consumption of 20 illicit drugs across urban areas of England using wastewater‐based epidemiology (WBE) surveillance at high temporal resolution. Design, setting, cases This study was conducted over a 12‐month period in 2022 sampling 24‐hour composite wastewater samples at 15 wastewater treatment plants (WWTPs ...
Helena Rapp‐Wright, Keng Tiong Ng, Derryn Grant, William Francis, Margarita White, Dimitris Evangelopoulos, Yuxing Liu, Konstantina Dimakopoulou, Sofia Zafeiratou, Dylan Wood, Chryshanthi Christy, Stav Friedman, Timothy W. Gant, Klea Katsouyanni, Leon P. Barron   +14 more
wiley   +1 more source

A comparison of opioid overdose risk behaviors by race and ethnicity among overdose survivors in Boston, MA, and San Francisco, CA. [PDF]

Harm Reduct J
Reed GE, McMahan VM, Chang YG, Johnson NL, Walley AY, Coffin PO, Harris MTH.   +6 more
europepmc   +1 more source

The association between sleep disturbance and stimulant use: A cross‐lagged examination

Addiction, Volume 121, Issue 8, Page 2116-2126, August 2026.
Abstract Background and aims Sleep disruptions increase the risk of substance misuse. Substance use—especially stimulants—can increase acute and chronic sleep dysfunction. This study aimed to estimate the associations between sleep disturbance and stimulant use over time among participants with stimulant use disorder (StUD).
Viviana E. Horigian, Renae D. Schmidt, Daniel J. Feaster, Rui Duan, Sophia T. Gonzalez, Kathryn Hefner, Dikla Shmueli‐Blumberg, Ashley Vena, Landhing M. Moran, Chloe A. DiCamillo, Shirin Shafazand, Susan Tross, Judith Feinberg   +12 more
wiley   +1 more source

Risk of opioid overdose during buprenorphine treatment for opioid use disorder in the fentanyl era. [PDF]

Addict Behav
Chambers LC, Hallowell BD, Zullo AR, Rodriguez M, Khan MA, Berk J, Gaither R, Daly M, Wightman RS, Beaudoin FL.   +9 more
europepmc   +1 more source

The Opioid Safety Toolkit: An interactive prescription opioid safety toolkit to increase opioid safety literacy and behaviours among people prescribed opioids for pain—a randomised controlled trial

Addiction, Volume 121, Issue 8, Page 2071-2082, August 2026.
Abstract Background and aims Prescription opioid‐related harm remains a significant public health concern. This study aimed to evaluate the efficacy of the Opioid Safety Toolkit, a co‐designed, interactive online resource, in increasing naloxone uptake and healthcare provider discussions among adults prescribed opioids for pain.
Suzanne Nielsen, Frederick Fox, Tina Lam, Alex Waddell, Monica Jung, Bosco Rowland, Jessica Watterson, Dhruv Basur, Chris Prawira, Joshua Paolo Seguin, Patrick Olivier, Jarrod McMaugh, Paul Dietze, Louisa Picco   +13 more
wiley   +1 more source

Clinical factors linked to xylazine exposure in emergency department patients with illicit opioid overdose. [PDF]

Addiction
Love JS, Vargas-Torres C, Aldy K, Brent J, Wax P, Culbreth R, Krotulski A, Campleman S, Logan B, Abston S, Li S, Manini AF, Fentalog Study Group.   +12 more
europepmc   +1 more source

Reimagining Hepatitis C Elimination: Time for Actions, Not Targets

Journal of the International AIDS Society, Volume 29, Issue 8, August 2026.
Marina B. Klein, Nadine Kronfli, Jim Young   +2 more
wiley   +1 more source

Cost-effectiveness of community-based interventions for reducing opioid overdose and non-overdose deaths: simulation modeling of HEALing Communities Study. [PDF]

Lancet Reg Health Am
Chhatwal J, Sahinkoc M, Chen Q, Dowd W, Xiao J, Zarkin GA, Aldridge A, Barocas JA, Cerdá M, Fareed N, Frazier LA, Hyder A, Keyes KM, Knott CE, LaRochelle M, Linas BP, Oga E, Roberts SM, Samet JH, Schackman BR, Seiber EE, Starbird LE, Villani J, Knudsen AB, Barbosa C.   +24 more
europepmc   +1 more source

Temporal Drivers of Opioid‐Related ED Visits: An Ensemble Machine Learning Study With Consensus‐Based Feature Attribution

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Identification of modifiable risk factors for prescription opioid use disorder (OUD)‐related emergency department (ED) visits (ICD‐10 F11.xx) is a clinical priority; however, most published models remain cross‐sectional and lack pharmacogenomic (PGx) enrichment or dual‐method feature confirmation. Using Virginia All‐Payer Claims Database (APCD)
R. Jerome Dixon, Elvin T. Price
wiley   +1 more source